A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 1, 2014, Pages 103-111

  Grippo, J F ^a   Zhang, W ^a   Heinzmann, D ^b   Yang, K H ^a,d   Wong, J ^a   Joe, A K ^a,e   Munster, P ^c   Sarapa, N ^a   Daud, A ^c  

^a HOFFMANN LA ROCHE INC   (United States)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNC Hamner Institute for Drug Safety Sciences   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Dose proportional; Melanoma; Pharmacokinetics; Phase I; Vemurafenib

Indexed keywords

VEMURAFENIB;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG COATING; DRUG DOSE REDUCTION; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METASTATIC MELANOMA; MIDDLE AGED; MORNING DOSAGE; MULTIPLE DRUG DOSE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STEADY STATE; TABLET FORMULATION; TIME; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84892802291     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2324-5     Document Type: Article

References (16)

1. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599
2. Søndergaard JN, Nazarian R, Wang Q, Guo D, Hsueh T, Mok S, Sazegar H, MacConaill LE, Barretina JG, Kehoe SM, Attar N, von Euw E, Zuckerman JE, Chmielowski B, Comin-Anduix B, Koya RC, Mischel PS, Lo RS, Ribas A (2010) Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 8:39
3. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A 105:3041-3046
4. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:347-351
5. Shull AY, Latham-Schwark A, Ramasamy P, Leskoske K, Oroian D, Birtwistle MR, Buckhaults PJ (2012) Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS ONE 7:e43369
6. Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445:851-857
7. Catalogue of Somatic Mutations in Cancer (COSMIC database): http://www.sanger.ac.uk/perl/genetics/CGP/cosmic; Release 51, Jan 2011
8. Wellbrock C, Karasarides M, Marais R (2004) The RAF proteins take centre stage. Nat Rev Mol Cell Biol 5:875-885
9. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819
10. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Hersey P, Kefford R, Lawrence D, Puzanov I, Lewis KD, Amaravadi RK, Chmielowski B, Lawrence HJ, Shyr Y, Ye F, Li J, Nolop KB, Lee RJ, Joe AK, Ribas A (2012) Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 366:707-714
11. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516
12. Chapman PB, Hauschild A, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto P, Testori A, Lorigan P, Dummer R, Sosman JA, Garbe C, Maio M, Nolop K, Nelson BJ, Joe AK, Flaherty KT, McArthur GA (2012) Updated overall survival results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib with dacarbazine in previously untreated patients with BRAFV600E-mutated melanoma [abstract]. J Clin Oncol 30(suppl):8502. Available at: http://www.asco.org/ASCOv2/MultiMedia/ Virtual+Meeting?&vmview=vm-session-presentations-view&confID= 114&sessionID=4825
13. Shah N, Iyer RM, Mair H-J, Choi DS, Tian H, Diodone R, Fähnrich K, Pabst-Ravot A, Tang K, Scheubel E, Grippo JF, Moreira SA, Go Z, Mouskountakis J, Louie T, Ibrahim PN, Sandhu H, Rubia L, Chokshi H, Singhal D, Malick W (2013) Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer stabilized solid dispersion prepared by a solvent controlled co-precipitation process. J Pharm Sci 102:967-981
14. Zelboraf® (vemurafenib) [prescribing information]. South San Francisco: Genentech, Inc.; 2012. Available at: http://www.gene.com/download/ pdf/zelboraf-prescribing.pdf. Last Assessed 8 Apr 2013
15. Roberts MS, Magnusson BM, Burczynski FJ, Weiss M (2002) Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751-790
16. Shou M, Lu W, Kari PH, Xiang C, Lu P, Cui D, Emary WB, Michel KB, Adelsberger JK, Brunner JE, Rodrigues AD (2005) Population pharmacokinetic modeling for enterohepatic recirculation in Rhesus monkey. Eur J Pharm Sci 26:151-161